Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cipla
Mallinckrodt
Colorcon
Novartis
QuintilesIMS
Express Scripts
Federal Trade Commission
Boehringer Ingelheim
Daiichi Sankyo

Generated: October 18, 2017

DrugPatentWatch Database Preview

Avanir Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for AVANIR PHARMS, and when can generic versions of AVANIR PHARMS drugs launch?

AVANIR PHARMS has two approved drugs.

There are fifteen US patents protecting AVANIR PHARMS drugs.

There are two hundred and eighty patent family members on AVANIR PHARMS drugs in thirty-one countries and eleven supplementary protection certificates in ten countries.

Summary for Applicant: Avanir Pharms

International Patents:280
US Patents:15
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
NUEDEXTA
dextromethorphan hydrobromide; quinidine sulfate
CAPSULE;ORAL021879-001Oct 29, 2010ABRXYesYes► Subscribe► Subscribe ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Avanir Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Avanir Pharms
NUEDEXTA
dextromethorphan hydrobromide; quinidine sulfate
CAPSULE;ORAL021879-001Oct 29, 2010► Subscribe► Subscribe
Avanir Pharms
NUEDEXTA
dextromethorphan hydrobromide; quinidine sulfate
CAPSULE;ORAL021879-001Oct 29, 2010► Subscribe► Subscribe
Avanir Pharms
NUEDEXTA
dextromethorphan hydrobromide; quinidine sulfate
CAPSULE;ORAL021879-001Oct 29, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for AVANIR PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
dextromethorphan hydrobromide and quinidine sulfate
Capsules20 mg/10 mg
NUEDEXTA
3/7/2011

Non-Orange Book Patents for Avanir Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,511,303Nasal delivery devices► Subscribe
7,347,201Nasal delivery devices► Subscribe
8,596,278Nasal devices► Subscribe
7,481,218Nasal devices► Subscribe
9,072,857Nasal delivery device► Subscribe
9,132,249Nasal devices► Subscribe
9,522,243Nasal devices► Subscribe
7,740,014Nasal devices► Subscribe
7,841,337Breath-actuated nasal delivery device► Subscribe
8,522,778Nasal devices► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Avanir Pharms Drugs

Country Document Number Estimated Expiration
Poland203959► Subscribe
Japan2014129384► Subscribe
European Patent Office1363692► Subscribe
Japan2013099535► Subscribe
World Intellectual Property Organization (WIPO)2008122791► Subscribe
Portugal1161274► Subscribe
China1981886► Subscribe
Russian Federation2004100276► Subscribe
European Patent Office1365826► Subscribe
SloveniaEP1539166► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Avanir Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2013Austria► SubscribePRODUCT NAME: KOMBINATION VON A) DEXTROMETHORPHAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE DEXTROMETHORPHANHYDROBROMID, UND INSBESONDERE DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT UND B) CHINIDIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE CHINIDINSULFAT, UND INSBESONDERE CHINIDINSULFATDIHYDRAT.; REGISTRATION NO/DATE: EU/1/13/833 20130626
8 5023-2013Slovakia► SubscribePRODUCT NAME: MONOHYDRAT DEXTROMETORFANU HYDROBROMIDU/- DIHYDRAT CHINIDINSULFATU; REGISTRATION NO/DATE: EU/1/13/833 20130624
2013 00059Denmark► SubscribePRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
90056-8Sweden► SubscribePRODUCT NAME: KOMBINATION AV (A) DEXTROMETORFAN ELLER ETT FARMACEUTISKT GODTAGBART SALT, PREKURSOR ELLER DERIVAT DAERAV, TEX. DEXTROMETORFAN-HYDROBROMID OCH I SYNNERHET DEXTROMETORFAN- HYDROBROMID MONOHYDRAT OCH (B) KINIDIN ELLER ETT FARMACEUTISKT GODTAGBART SALT, PREKURSOR ELLER DERIVAT DAERAV, TEX. KINIDINSULFAT OCH I SYNNERHET KINIDINSULFAT DIHYDRAT; REG. NO/DATE: EU/1/13/833 20130626
2013 00059Denmark► SubscribePRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
0130030 00105Estonia► SubscribePRODUCT NAME: DEKSTROMETORFAAN / KINIDIIN;REG NO/DATE: K(2013)4096 (LOPLIK) 26.06.2013
00626Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN: (A) DEXTROMETHORFAN, DESGEWENST; REGISTRATION NO/DATE: EU/1/13/833 20130624
1Finland► Subscribe
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Argus Health
McKesson
Novartis
US Army
Baxter
Dow
Harvard Business School
UBS
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot